What percentage of people with type 2 diabetes have cardiorenal complications?
What are the key metabolic risks?
What role do SGLT2 inhibitors and GLP-1 receptor agonists have to play?
How many people who need these agents receive them?
What needs to change to fully mitigate cardiorenal risks?
Is there a perception that diabetes care is not the responsibility of cardiologists?
What is the link between diabetes and cardiovascular outcomes?
What have we learnt from the cardiovascular outcomes trials with SGLT2 inhibitors and GLP-1 receptor agonists?
What role could these agents play in the inpatient cardiovascular care setting?
What did you hope to show with the TrialNet study?
Have there been any surprises in the results?
How can this information shape future treatment options for type 1 diabetes?
What are incretins, and are they a new concept?
How do incretins stimulate insulin secretion?
How do the hormones GLP-1 and GIP interact?
How can broader understanding of the incretin story drive the development of novel therapies?
What is the problem your project aimed to address?
Can you provide an overview of your project and some main findings?
How does income and immigration status affect people’s ability to manage their diabetes?
How can social media help?
What new features would you like to see developed?
What is the definition of youth-onset type 2 diabetes?
What are the unique challenges of youth-onset type 2 diabetes?
Is there a genetic picture emerging?
What are the biological insights provided by genetic studies on youth-onset diabetes?
How can this emerging genetic information shape future management?
What are the links between vascular stiffness and type 2 diabetes?
Are we seeing these changes at a younger age?
How was the TODAY study conducted?
What was the most important result – and was it what you expected?
How will the results of TODAY affect treatment decisions for people with type 2 diabetes?
How do diabetes rates in children and young people compare with those from 10 or 20 years ago?
What is driving the changes that we are seeing?
What are your projections for the diabetes burden in the US over the next 40 years?
How can we tackle this?